权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Vagal Nerve Stimulation & Antidepressants: c-Fos, deltaFosB and TrkB Activation

迷走神经刺激

基本信息

批准号：
8267085
负责人：
ALAN FRAZER
金额：
$ 33.08万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-08-04 至 2014-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8267085
关键词：
Acute Address Adrenergic Receptor Affect Agonist Amygdaloid structure Animals Antidepressive Agents Area Autoreceptors Behavioral Biological Markers Brain Brain region Brain-Derived Neurotrophic Factor Chronic Chronic Disease Corpus striatum structure Data Desipramine Devices Electrodes Epilepsy FDA approved FOS gene Frequencies Gene Expression Goals Heart Rate Hour Immediate-Early Genes Immunohistochemistry Lesion Major Depressive Disorder Manufacturer Name Measures Mental Depression Monitor Nerve Neuraxis Neuromodulator Neurons Neurotransmitters Neurotrophic Tyrosine Kinase Receptor Type 2 Norepinephrine Nucleus solitarius Oxidopamine Patients Peripheral Phosphorylation Protocols documentation Quantitative Autoradiography Rattus Receptor Activation Refractory Resistance Role Selective Serotonin Reuptake Inhibitor Serotonin Serotonin Receptor 5-HT1A Sertraline Staining method Stains Stress Swimming System Telemetry Testing Time Work cingulate cortex clinical effect clinically relevant density dorsal raphe nucleus extracellular indexing inhibitor/antagonist noradrenergic preclinical study receptor sensitivity research study respiratory reuptake vagus nerve stimulation

项目摘要

ABSTRACT Almost 30% of patients with major depressive disorder have a chronic illness that is treatment refractory. Vagus nerve stimulation (VNS) has recently been approved by the FDA for treatment refractory depression. However, there have been few pre-clinical studies addressing the central actions of VNS that may be relevent for its antidepressant effect. We completed recently some preliminary studies in which VNS was administred either acutely or chronically to non-anesthetized rats using clinically-relevant stimulation parameters. Both functional neuroanatomical and behavioral effects were observed. The goal of this proposal is to expand and amplify these observations so as to evaluate more comprehensively effects produced by VNS in brain and the mechanisms underlying such effects. Our overall hypothesis is that VNS produces its beneficial clinical effects, as measured by reduced immobility in the forced swim test (FST) in rats, by activation of multiple neurotransmitter/neuromodulator systems in brain, in particular serotonin or norepinephrine and/or brain- derived neurotrophic factor containing neurons (through phosphorylation of TrkB receptors). To test these ideas, we will: (1) initially optimize stimulation parameters, using both acute and chronic (3 week) VNS by determining behavioral effects it produces in the FST and compare its effects to those produced by the selective noradrenergic reuptake inhibitor, desipramine, and the selective serotonin reuptake inhibitor, sertraline, (2) use the chronic VNS protocol that has the best effect in the FST to measure its effects on c-Fos, ¿FosB, Egr-1, activation of TrkB, ¿1-adrenoceptors, and somatodendritic 5-HT autoreceptor sensitivity and compare results to those caused by chronic treatment with desipramine or sertraline, and (3) test the role of norepinephrine and serotonin in the antidepressant-like effect of chronic VNS, desipramine and sertraline by lesioning rats with either 6-hydroxydopamine or 5,7- dihyroxytryptamine. Immunohistochemistry will be used to measure c-Fos, ¿FosB, Egr-1, and phosphorylated TrkB. Quantitative autoradiography will be used to measure ¿1-adrenoreceptors. DPAT-induced changes in extracellular 5-HT in the striatum will be used as an index of autoreceptor sensitivity. The results could provide important, new information regarding the central nervous system effects of VNS that are important for the treatment of depression. PROJECT NARRATIVE About 30% of patients with major depressive disorder are resistant to standard antidepressant therapy. Vagal nerve stimulation (VNS) was approved recently for such refractory patients; it is moderately effective, but how it works is unknown. Our studies will evaluate comprehensively effects produced by VNS in the brain of rats and the mechanisms underlying such effects, so as to provide data to allow VNS to become even more effective.

摘要近30%的重度抑郁症患者患有治疗难治的慢性病。迷走神经刺激(VNS)最近被FDA批准用于治疗难治性抑郁症。然而，很少有临床前研究涉及可能相关的VNS的中枢作用因为它的抗抑郁作用。我们最近完成了一些对VNS进行管理的初步研究使用临床相关的刺激参数对非麻醉大鼠进行急性或慢性刺激。两者都有观察功能、神经解剖学和行为学方面的影响。这项提议的目标是扩大和放大这些观察，以便更全面地评估VNS在大脑和大脑中产生的影响这种影响背后的机制。我们的总体假设是VNS产生了有益的临床效果，通过大鼠强迫游泳试验(FST)中减少的不动来衡量，通过激活多个大脑中的神经递质/神经调节系统，特别是5-羟色胺或去甲肾上腺素和/或脑- 含有衍生神经营养因子的神经元(通过TrkB受体的磷酸化)。为了测试这些想法，我们将：(1)初步优化刺激参数，使用急性和慢性(3周)VNS通过确定它在FST中产生的行为影响，并将其影响与选择性去甲肾上腺素再摄取抑制剂，地塞帕明，和选择性5-羟色胺再摄取抑制剂，舍曲林，(2)使用FST中效果最好的慢性VNS方案来衡量其对c-Fos的影响， FosB、Egr-1、TrkB的激活、1-肾上腺素受体和躯体树突状细胞5-羟色胺自身受体敏感性将结果与地昔帕明或舍曲林慢性治疗的结果进行比较，以及(3)测试去甲肾上腺素和5-羟色胺在慢性VNS、地塞帕明和舍曲林抗抑郁药样作用中的作用用6-羟基多巴胺或5，7-二羟色胺损毁大鼠。免疫组织化学将用于测定c-Fos、？FosB、Egr-1和磷酸化TrkB。定量放射自显影将用于测量1-肾上腺素受体。DPAT诱导的纹状体细胞外5-羟色胺的变化将被用作自身受体敏感性指数。这些结果可能会提供关于中央银行的重要新信息。 VNS对神经系统的影响对抑郁症的治疗非常重要。项目叙事大约30%的重度抑郁症患者对标准的抗抑郁药物治疗有抵抗力。迷路的神经刺激(VNS)最近被批准用于此类难治性患者；它是适度有效的，但它是如何作品不为人所知。我们的研究将全面评估VNS对大鼠大脑和大脑的影响这种影响背后的机制，以便提供数据，使VNS变得更加有效。